Oculus Innovative Sciences and Lipogrid of Sweden Announce Strategic Collaboration for Topical Dermatology Drug Delivery
March 30, 2016 04:05 ET
|
Sonoma Pharmaceuticals, Inc.
NORRTALJE, Sweden and PETALUMA, Calif., March 30, 2016 (GLOBE NEWSWIRE) -- Oculus Innovative Sciences, Inc. (NASDAQ:OCLS) (NASDAQ:OCLSW), a specialty pharmaceutical company that develops and...
Oculus Innovative Sciences to Present at the Sidoti Emerging Growth Conference
March 24, 2016 04:05 ET
|
Sonoma Pharmaceuticals, Inc.
PETALUMA, Calif., March 24, 2016 (GLOBE NEWSWIRE) -- Oculus Innovative Sciences, Inc. (NASDAQ:OCLS) (NASDAQ:OCLSW), a specialty pharmaceutical company that develops and markets solutions...
Oculus Innovative Sciences Announces Multi-Year Licensing Agreement with Manna Pro Products, LLC, for MicrocynAH® Animal Healthcare Products
March 23, 2016 04:05 ET
|
Sonoma Pharmaceuticals, Inc.
ST. LOUIS and PETALUMA, Calif., March 23, 2016 (GLOBE NEWSWIRE) -- Oculus Innovative Sciences, Inc. (NASDAQ:OCLS, warrants OCLSW), a specialty pharmaceutical company that develops and...
Oculus Innovative Sciences Announces Pricing of $3.4 Million Underwritten Public Offering
March 18, 2016 08:41 ET
|
Sonoma Pharmaceuticals, Inc.
PETALUMA, Calif., March 18, 2016 (GLOBE NEWSWIRE) -- Oculus Innovative Sciences, Inc. (NASDAQ: Common Stock – OCLS, Warrants – OCLSW) today announced the pricing of an underwritten public offering...
Oculus Innovative Sciences Announces Proposed Underwritten Public Offering of Common Stock and Warrants
March 17, 2016 19:41 ET
|
Sonoma Pharmaceuticals, Inc.
PETALUMA, Calif., March 17, 2016 (GLOBE NEWSWIRE) -- Oculus Innovative Sciences, Inc. (NASDAQ: Common Stock – OCLS, Warrants – OCLSW) today announced that it intends to offer and sell, subject to...
Oculus Innovative Sciences to Present at the Roth Capital Partners 28th Annual Conference
March 09, 2016 03:05 ET
|
Sonoma Pharmaceuticals, Inc.
PETALUMA, Calif., March 09, 2016 (GLOBE NEWSWIRE) -- Oculus Innovative Sciences, Inc. (NASDAQ:OCLS) (warrants OCLSW), a specialty pharmaceutical company that develops and markets solutions...
Oculus Innovative Sciences Receives European Approval to Market Lasercyn Indicated for Use Following Laser Skin Resurfacing
March 03, 2016 03:05 ET
|
Sonoma Pharmaceuticals, Inc.
PETALUMA, Calif., March 03, 2016 (GLOBE NEWSWIRE) -- Oculus Innovative Sciences, Inc. (NASDAQ:OCLS) (warrants OCLSW), a specialty pharmaceutical company that develops and markets solutions...
Maxim Group Hosts Key Opinion Leaders Discussing “Breakthroughs in Dermatology” Relating to Products From Oculus Innovative Sciences
February 18, 2016 04:05 ET
|
Sonoma Pharmaceuticals, Inc.
PETALUMA, Calif., Feb. 18, 2016 (GLOBE NEWSWIRE) -- Oculus Innovative Sciences, Inc. (NASDAQ:OCLS) (warrants OCLSW), a specialty pharmaceutical company that develops and markets solutions for...
Oculus Innovative Sciences to Present at the Source Capital Group's 2016 Disruptive Growth & Healthcare Conference
February 05, 2016 04:05 ET
|
Sonoma Pharmaceuticals, Inc.
PETALUMA, Calif., Feb. 05, 2016 (GLOBE NEWSWIRE) -- Oculus Innovative Sciences, Inc. (NASDAQ:OCLS) (tradable warrants OCLSW) today announced that Jim Schutz, chief executive officer, and Bob...
Oculus Innovative Sciences Reports Third Quarter Financial Results
February 04, 2016 16:05 ET
|
Sonoma Pharmaceuticals, Inc.
U.S. Dermatology and Rest of the World Sales Drive Product Revenue Growth of 40% Conference Call at 4:30pm ET Today PETALUMA, Calif., Feb. 04, 2016 (GLOBE NEWSWIRE) -- Oculus Innovative...